+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID07906106

Randomized, Double-blind Study of SFG-02 Transdermal Patch Compared to Placebo in Adults With Underactive Bladder

Led by Juro Sciences Inc. · Updated on 2026-10-30

70

Participants Needed

16

Research Sites

13 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effect of a transdermal formulation called SFG-02 on Bladder Voiding Efficiency BVE in adults with Underactive Bladder UAB. This Phase 2a proof-of-concept study aims to assess both the impact on bladder function and the safety of the treatment compared to a placebo. Participants have symptoms like urinary hesitancy, straining to void, or weak urinary stream and meet specific bladder function criteria. Participants will undergo a 4-week placebo run-in period followed by 8 weeks of daily application of either the SFG-02 patch or a placebo patch. Each patch is worn for a full day, and participants will apply a new patch every day for a total treatment duration of 12 weeks. The study uses a randomized, double-blind design to compare the active drug to placebo. During the study, participants will visit the clinic every 2 to 4 weeks for checkups and tests. They will keep diaries to record bladder symptoms and the timing of patch changes. Researchers will monitor changes in Bladder Voiding Efficiency from baseline to the end of treatment as the primary outcome. Safety will also be assessed through laboratory tests and heart monitoring, with the entire participation lasting approximately 12 weeks.

CONDITIONS

Brief Title

A Proof-Of-Concept (POC) Study of SFG-02 Transdermal Formulation in Participants With Underactive Bladder (UAB)

Research Team

J

Juro Sciences

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here